Acceptance and commitment therapy for psychosomatic outcomes and quality of life in adults with cancer: Systematic review and meta-analysis.
[PURPOSE] Acceptance and commitment therapy (ACT) is widely used for cancer patients, yet its effects are not well understood with respect to psychosomatic outcomes and quality of life (QoL).
- 연구 설계 meta-analysis
APA
Kang Z, Xu Y, et al. (2026). Acceptance and commitment therapy for psychosomatic outcomes and quality of life in adults with cancer: Systematic review and meta-analysis.. European journal of oncology nursing : the official journal of European Oncology Nursing Society, 81, 103141. https://doi.org/10.1016/j.ejon.2026.103141
MLA
Kang Z, et al.. "Acceptance and commitment therapy for psychosomatic outcomes and quality of life in adults with cancer: Systematic review and meta-analysis.." European journal of oncology nursing : the official journal of European Oncology Nursing Society, vol. 81, 2026, pp. 103141.
PMID
41712974
Abstract
[PURPOSE] Acceptance and commitment therapy (ACT) is widely used for cancer patients, yet its effects are not well understood with respect to psychosomatic outcomes and quality of life (QoL). This review aims to explore the effects of ACT on the psychosomatic outcomes and QoL of cancer patients.
[METHODS] Eleven electronic databases were searched from inception to December 2025. Two authors independently extracted the data. RevMan 5.4 was used for data analysis and RoB 2.0 and GRADE were used for quality assessment.
[RESULTS] Forty studies were included, 30 of which were eligible for meta-analysis. The meta-analysis revealed that compared with the control, ACT used alone had significant effects on hope [SMD = 3.01, 95% CI (0.69, 5.34)], psychological flexibility [SMD = -1.42, 95% CI (-1.96, -0.87)], psychological distress [SMD = -0.79, 95% CI (-1.45, -0.13)], anxiety [SMD = -0.92, 95% CI (-1.70, -0.14)], depressive symptoms [SMD = -0.95, 95% CI (-1.50, -0.39)], fatigue [SMD = -0.81, 95% CI (-1.55, -0.06)] and QoL [SMD = 1.07, 95% CI (0.14, 2.00)] in cancer patients. ACT used in combination can relieve depressive symptoms [SMD = -2.04, 95% CI (-2.44, -1.65)], anxiety [SMD = -2.10, 95% CI (-2.78, -1.41)] and fatigue [SMD = -2.49, 95% CI (-2.90, -2.08)].
[CONCLUSION] ACT can improve hope, psychological flexibility, psychological distress, anxiety, depressive symptoms and the QoL of cancer patients. Future studies should expand sample sizes and optimize designs to advance research with cancer patients.
[METHODS] Eleven electronic databases were searched from inception to December 2025. Two authors independently extracted the data. RevMan 5.4 was used for data analysis and RoB 2.0 and GRADE were used for quality assessment.
[RESULTS] Forty studies were included, 30 of which were eligible for meta-analysis. The meta-analysis revealed that compared with the control, ACT used alone had significant effects on hope [SMD = 3.01, 95% CI (0.69, 5.34)], psychological flexibility [SMD = -1.42, 95% CI (-1.96, -0.87)], psychological distress [SMD = -0.79, 95% CI (-1.45, -0.13)], anxiety [SMD = -0.92, 95% CI (-1.70, -0.14)], depressive symptoms [SMD = -0.95, 95% CI (-1.50, -0.39)], fatigue [SMD = -0.81, 95% CI (-1.55, -0.06)] and QoL [SMD = 1.07, 95% CI (0.14, 2.00)] in cancer patients. ACT used in combination can relieve depressive symptoms [SMD = -2.04, 95% CI (-2.44, -1.65)], anxiety [SMD = -2.10, 95% CI (-2.78, -1.41)] and fatigue [SMD = -2.49, 95% CI (-2.90, -2.08)].
[CONCLUSION] ACT can improve hope, psychological flexibility, psychological distress, anxiety, depressive symptoms and the QoL of cancer patients. Future studies should expand sample sizes and optimize designs to advance research with cancer patients.
MeSH Terms
Humans; Quality of Life; Neoplasms; Acceptance and Commitment Therapy; Adult
같은 제1저자의 인용 많은 논문 (4)
- Repurposing rosmarinic acid as an anti-colorectal cancer agent through bolstering T cell anti-tumor immunity by enhancing activation of MEK1-mediated TCR signaling.
- Current landscape of PDT-based combination therapy for cutaneous squamous cell carcinoma: From molecular mechanisms to clinical practice.
- Immunosenescence phenotypes and prognostic significance of CD8 + CD28- T cells in AIDS-related non-Hodgkin lymphoma.
- Super-enhancers mediates SLC7A11 via FOXA1 to regulate disulfidptosis in prostate cancer.